Results 241 to 250 of about 70,073 (274)
Some of the next articles are maybe not open access.

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.

The Lancet Oncology, 2015
C. Ryan   +24 more
semanticscholar   +1 more source

Cancer statistics, 2022

Ca-A Cancer Journal for Clinicians, 2022
Rebecca L Siegel   +2 more
exaly  

Cancer Statistics, 2021

Ca-A Cancer Journal for Clinicians, 2021
Rebecca L Siegel, Kimberly D Miller
exaly  

Metastatic castrate-resistant prostate cancer

Urologic Oncology: Seminars and Original Investigations, 2015
openaire   +2 more sources

Enzalutamide in Castration-Resistant Prostate Cancer

New England Journal of Medicine, 2018
Giacomo, Bregni   +2 more
openaire   +4 more sources

Castration-resistant Prostate Cancer

2016
Vikash Kumar   +2 more
openaire   +1 more source

[Castration resistant prostate cancer 2011].

Aktuelle Urologie, 2011
Our understanding of - as well as our approach to - castration resistant prostate cancer is currently undergoing major changes. New drugs like the CYP-17 inhibitor abiraterone have shown that even in the "hormone refractory" stage the progression of prostate cancer is still driven by signaling of the androgen receptor.
openaire   +1 more source

Cancer statistics, 2020

Ca-A Cancer Journal for Clinicians, 2020
Rebecca L Siegel, Kimberly D Miller
exaly  

Home - About - Disclaimer - Privacy